Navigation Links
Mylan Launches Generic Lipitor® in Five European Countries
Date:5/11/2012

PITTSBURGH and LYON, France, May 11, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 mg and 80 mg in France, Belgium, the UK, the Netherlands and Ireland. Mylan has received marketing authorization from each country's respective health authority to begin selling its product immediately. Atorvastatin Calcium is the generic version of Pfizer's Lipitor® Tablets. This product is indicated for the prevention of cardiovascular disease and hypercholesterolemia.

Mylan CEO Heather Bresch said: "We are pleased to provide access to generic Lipitor to more than 4 million patients in five countries across Europe. Mylan is committed to expanding access to high quality medicine in Europe and around the world. Mylan's launch of Atorvastatin Calcium Tablets will help to provide health care systems in these markets with an estimated $700 million (euro 500 million) of savings in 2012 associated with the generic availability of this important medicine."

In France, Belgium, the UK, the Netherlands and Ireland, Lipitor had total sales of $1.6 billion (euro 1.126 billion) for the twelve months ending Dec. 31, 2011, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
2. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
3. Mylan Launches Generic Version of Zyprexa® Tablets
4. Mylan Launches First Generic Version of Lescol® Capsules
5. Mylan Schedules First Quarter 2012 Financial Results Conference Call and Live Webcast
6. Mylan One of First to Launch Generic Version of Boniva®
7. Mylan Canada Receives Health Canada Approval for Generic Version of Crestor®
8. Mylan Continues to Pursue Damages and Injunction Against Sunovions Brovana® in Ongoing Litigation
9. Mylan Pharmaceuticals President Tony Mauro Elected Chairman of GPhA
10. Mylan Secures an Additional $300 Million of Committed Financing
11. Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2019)... ... September 13, 2019 , ... ... Montreal provided a plethora of breakthrough research studies including several cancer related ... detect breast cancer, response prediction of cancer immunotherapies and whole body, real-time ...
(Date:9/14/2019)... , ... September 14, 2019 , ... ... continuing medical education (CME) courses, is announcing its attempt at a world record ... opportunity to prepare for the PANRE while earning 30 CME credits in 30 ...
(Date:9/11/2019)... ... September 12, 2019 , ... Understanding the Drug Supply ... Webinar, Thursday, Sept. 26, 2019, 1:30-3:00 p.m. EDT, https://www.fdanews.com/understanding-the-dscsa , Need ... the company clear on nuances of the guidelines regulating the drug supply chain? ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... 17, 2019 , ... What if a drug that sits ... patients? In companion presentations at the American Society for Therapeutic Radiation Oncology (ASTRO) ... evidence that low-dose aspirin and other anti-inflammatories may improve survival in patients undergoing ...
(Date:9/17/2019)... ... September 17, 2019 , ... Specialty Technical Publishers (STP) and ... Protocol Consortium (IAPC) EHS audit protocol for Japan . Leading companies around ... EHS regulatory obligations and rapidly collect, share, archive, and export audit findings in ...
(Date:9/17/2019)... ... September 17, 2019 , ... CORE Medical & Wellness, ... (Jenny) Gartshteyn to their team of expert physicians. Dr. Gartshteyn completed her Rheumatology ... Appointment of Assistant Professor in Medicine for the Division of Hospitalist Medicine. , ...
(Date:9/14/2019)... ... , ... GreenTheVoteOk , one of the most reliable online resource providers ... most relevant and important developments in the fast-changing world of legalized CBD. , ... across the world suffering from different difficult-to-treat ailments, people need to identify brands that ...
(Date:9/11/2019)... ... September 11, 2019 , ... Workplace ... have struggled to solve injury risks which lead to musculoskeletal disorders (MSDs). ... solution developed by the team at Soter Analytics helps avoid ergonomic ...
Breaking Medicine News(10 mins):